jeudi 20 décembre 2018

Onco Actu du 20 décembre 2018

1. Biologie

FSU researchers identify ways breast cancer avoids immune system detection [Florida State University]

Immune cells cast DNA ‘webs’ that may help ovarian cancer spread [Cancer Resarch UK]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Recommendations by UK's NICE [Genome Web]

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer [NICE]

United Kingdom’s National Institute for Health and Care Excellence (NICE) Recommends NanoString’s Prosigna Breast Cancer Gene Signature Assay to Guide Chemotherapy Treatment Decisions for Qualified Early-Stage Invasive Breast Cancer Patients [nanoString]

4.7 Dép., diag. & prono. - Col de l'utérus

Too soon to say cervical cancer DNA test will ‘revolutionise screening’ [Cancer Research UK]

5. Traitements

Pancreatic cancer [NICE]

5.10 Traitements - Essais

Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer [AstraZeneca]

Whole- and Partial-Breast Radiation Effective at Preventing Breast Cancer from Returning [NCI]

AstraZeneca's ovarian cancer and anemia treatments meet goals in late-stage studies [Reuters]

5.12.3 Immunothérapies-combinaisons

Vaccine, Checkpoint Drugs Combination Shows Promise for Pancreatic Cancers [Johns Hopkins]

5.12.6 Immunothérapies - AMM

FDA approves pembrolizumab for Merkel cell carcinoma [FDA]

5.12.7 Immunothérapies - vaccins

Anticancer Vaccines Gain new Lease of Life with Personalisation Techniques [ESMO Press Release]

5.2.1 Pharma - Partenariats

Expect more transparency around pharma's advocacy group partnerships in 2019 [FiercePharma]

5.2.3 Pharma - économie

The valsartan carcinogen mess taught pharma a surprise manufacturing lesson. Will 2019 bring more? [FiercePharma]

5.3 Traitements - FDA, EMA, NICE...

Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics - Guidance for Industry [FDA]

5.3.4 Traitements - AMM (FDA, EMA,...)

FDA approves olaparib for first-line maintenance of BRCA-mutated advanced ovarian cancer [FDA]

BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer [Myriad]

Lynparza approved by US FDA for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer [AstraZeneca]

5.4 Traitements - Economie

NICE recommends Lenvima as alternative first-line therapy for advanced liver cancer [Pharmafile]

Lenvatinib for untreated advanced hepatocellular carcinoma [NICE]

6.1 Observation

Prostate cancer scoring method may underestimate mortality risk in black men [Dana-Farber Cancer Institute]

6.10.1 Politiques (USA)

Is a God-fearing scientist the next casualty of the Trump White House? [Washington Examiner]

6.12 Ethique

Top Cancer Doctor Resigns as Editor of Medical Journal [NY Times]

6.2 Implants mammaires

Breast implants linked to cancer withdrawn from sale in Europe [The Guardian]

6.6 Publications

University of California squares off against major publisher, with big stakes for access to research [STAT]

Plan S: The Ambitious Initiative to End the Reign of Paywalls [The Scientist]

6.8 Communication

No peak in sight: Cancer marketing spreads across media landscape, from TV to digital [FiercePharma]